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Abstract
AIM: To determine the discriminatory performance 
of fatty liver index (FLI) for non-alcoholic fatty liver 
disease (NAFLD).
METHODS: The data of 5052 subjects aged over 18 
years were analyzed. FLI was calculated from body 
mass index, waist circumference (WC), triglyceride, 
and gamma glutamyl transferase data. Logistic 
regression analysis was conducted to determine the 
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Observational Study
Fatty liver index vs  waist circumference for predicting 
non-alcoholic fatty liver disease
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a chronic 
condition characterized by the accumulation of fat in 
the liver in the absence of other causes of steatosis, 
including excess consumption of alcohol or drugs[1]. 
The prevalence of this condition in western countries 
varies from 20% to 30% depending on applied 
diagnostic tools, the population under study, and 
related definitions[2]. Although still lower than that 
found in western countries, there is an increasing trend 
in NAFLD prevalence in Asian countries, due to the 
recent increase in the incidence of obesity, metabolic 
syndrome, and diabetes type 2[3]. Additionally, while 
the prevalence of NAFLD is estimated to be 15%-20% 
in the general Asian population, one population-
based study on adults in northern Iran resulted in an 
incidence of almost 44%[3,4]. NAFLD can lead to a wide 
range of clinical conditions, from simple steatosis to 
cirrhosis, or even hepatocellular carcinoma[5-9].
Although the two most common methods used in 
the diagnosis of fatty liver are histologic methods and 
imaging procedures, no single diagnostic procedure 
has been shown to be reliable enough in the diagnosis 
of fatty liver[10-12]. Despite liver biopsy being the gold 
standard procedure for the diagnosis of NAFLD, it is an 
invasive and expensive tool that has some health risks 
and economic costs[11-14].
Recently, a number of indices were introduced to 
diagnose NAFLD that consist of simple measures[15-18]. 
Fatty liver index (FLI) is one of these indices developed 
as a convenient tool based on body mass index (BMI), 
waist circumference (WC), triglyceride (TG), and 
gamma glutamyl transferase (GGT) levels[18]. In one 
previous study, this index showed good predictive 
performance in the diagnosis of NAFLD, with an AUC 
of 0.813[19]. When a diagnostic tool displays accurate 
predictive capability, it is important that an optimal 
cutoff point is determined. To the best knowledge 
of the authors, no such study has been conducted 
among the Iranian population. Therefore, this study 
was carried out to assess the discriminatory ability of 
FLI in the diagnosis of NAFLD among a population in 
northern Iran, as well as to propose an optimal cutoff 
point for FLI.
MATERIALS AND METHODS
Study participants
Of 6140 participants in a baseline cohort study 
conducted among individuals aged between 10 and 90 
years-of-age, data from 5052 participants aged 18 or 
older were analyzed in the present study. The baseline 
study was carried out in Amol, a densely-populated 
city in northern Iran. Local health centers, where 
almost all study participants had health record files, 
were used to collect the data. Sampling for the cohort 
study is explained elsewhere[20]. A schematic diagram 
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association between FLI and NAFLD. The discriminatory 
performance of FLI in the diagnosis of NAFLD was 
evaluated by receiver operating characteristic analysis. 
Area under the curves (AUCs) and related confidence 
intervals were estimated. Optimal cutoff points of FLI in 
the diagnosis of NAFLD were determined based on the 
maximum values of Youden’s index.
RESULTS: The mean age of men and women in the 
study population were 44.8 ± 16.8 and 43.78 ± 15.43, 
respectively (P  = 0.0216). The prevalence of NAFLD 
was 40.1% in men and 44.2% in women (P  < 0.0017). 
FLI was strongly associated with NAFLD, so that even 
a one unit increase in FLI increased the chance of 
developing NAFLD by 5.8% (OR = 1.058, 95%CI: 
1.054-1.063, P  < 0.0001). Although FLI showed good 
performance in the diagnosis of NAFLD (AUC = 0.8656 
(95%CI: 0.8548-0.8764), there was no significant 
difference with regards to WC (AUC = 0.8533, 95%CI: 
0.8419-0.8646). The performance of FLI was not 
significantly different between men (AUC = 0.8648, 
95%CI: 0.8505-0.8791) and women (AUC = 0.8682, 
95%CI: 0.8513-0.8851). The highest performance with 
regards to age was related to the 18-39 age group (AUC 
= 0.8930, 95%CI: 0.8766-0.9093). The optimal cutoff 
points of FLI were 46.9 in men (sensitivity = 0.8242, 
specificity = 0.7687, Youden’s index = 0.5929) and 53.8 
in women (sensitivity = 0.8233, specificity = 0.7655, 
Youden’s index = 0.5888).
CONCLUSION: Although FLI had acceptable discri-
minatory power in the diagnosis of NAFLD, WC was 
a simpler and more accessible index with a similar 
performance. 
Key words: Non-alcoholic fatty liver disease; Fatty liver 
index; Waist circumference; Body mass index; Optimal 
cutoff points; Discriminatory performance
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The present study was carried out to evaluate 
the discriminatory capability of fatty liver index in the 
diagnosis of non-alcoholic fatty liver disease (NAFLD) 
among the general population of northern Iran. Our 
results showed that the chance of NAFLD occurrence 
was increased by 5.8% after a one unit increase in fatty 
liver index (FLI). Although we found that FLI has good 
discriminatory power, its capability was not superior to 
that of waist circumference. 
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of study participants and exclusion criteria is shown in 
Figure 1.
Data collection
Weight, height, waist circumference, hip circumference, 
and blood pressure were measured in health centers, 
where trained healthcare staff members were re-
sponsible for data collection. Height was measured 
while the participants were standing with their 
heels and buttocks pressed up against a wall. Waist 
circumference was determined at the midpoint 
between the lowest costal ridge and the upper border 
of the iliac crest. The largest circumference between 
waist and knee was determined as hip circumference. 
Measurements were performed with a non-stretchable 
and accurately calibrated scale with 0.5 cm precision.
Blood pressure was measured, after a minimum 
5-min rest period in a quiet room, with the use of a 
fitted cuff while participants were in the sitting position 
with their back supported and legs uncrossed. Systolic 
and diastolic blood pressures were determined and 
recorded as the first appearance and disappearance of 
Korotkoff sounds, respectively.
A venous blood sample was drawn from each 
participant following 12-h fasting to assess fasting 
blood sugar (FBS) and lipid profiles. All tests, including 
FBS, triglycerides (TGs), high-density lipoprotein (HDL), 
low-density lipoprotein, and cholesterol were assessed 
enzymatically using the BS200 Auto analyzer (Mindray, 
China). Screening tests for hepatitis B and C viral 
markers, as well as for autoimmune hepatitis, were 
performed. 
Ten percent of the blood samples were evaluated 
by the Iranian National Reference Laboratory, with the 
coefficients of variation being between 1.7% and 3.8% 
of all laboratory values.
NAFLD was determined via evidence of hepatic 
steatosis in the sonogram and a lack of evidence of 
other causes of acute or chronic hepatitis. Evidence of 
secondary hepatic fat accumulation, such as significant 
alcohol consumption, use of steatogenic medication, 
or hereditary disorders, was also used to determine 
NAFLD. 
All ultrasound examinations were carried out by a 
single sonographer who was an expert in the field of 
radiology. A 3-5 MHz transducer was used to examine 
the liver parenchyma and thereby provide sagittal, 
longitudinal, lateral, and intercostal views. Steatosis 
was confirmed if a marked increase of hepatic 
echogenicity was diagnosed or if the hepatic vessels 
and diaphragm appeared abnormal.
Homeostasis model assessment-insulin resistance 
(HOMA-IR) was calculated based on the following 
formula:
HOMA-IR = [insulin (mU/mL) × Glucose (mg/dL)]/405
FLI was calculated based on laboratory and 
anthropometric measures, including TG, GGT, BMI, 
and WC, by using the following formula: 
FLI = [e0.953 × ln (TG) + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × WC - 15.745 
/(1 + e0.953 × ln (TG) + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × WC - 15.745)] 
× 100
Statistical analysis
The capability of FLI to discriminate between subjects 
with and without NAFLD was evaluated using receiver 
operating characteristic (ROC) curve, for which the 
sensitivity of infinite decision thresholds of FLI was 
plotted against their false positive rates and thus the 
related areas under the curves (AUCs) were calculated. 
The lower boundary line for AUC was considered to be 
0.5, with a significantly greater area than 0.5 showing 
some ability of FLI to discriminate between patients 
with and without NAFLD. The optimal cutoff point of 
FLI was also determined using maximal values of 
Youden’s J statistics [max (J = sensitivity + specificity 
- 1)]. The value of FLI corresponding to a maximum 
value of the Youden’s index was considered the optimal 
cutoff point for FLI. 
Multivariable logistic regression analysis was 
conducted on NAFLD as an outcome variable alongside 
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7104 subjects aged 10-90 yr 
were selected to participate in 
the cohort study
6296 subjects agree
6143 subjects 10-90 yr were 
included in the cohort study
5797 subjects of cohort 
study were ≥ 18 yr
5311 subjects were included 
in the present study 
Finally the data of 5052 
subjects were analyzed 
808 subjects did not agree to 
participate in the study
153 pregnant women were 
excluded
346 subjects < 18 were 
excluded
486 subjects were excluded 
due to a history of excessive 
alcohol consumption, a 
positive test of HBsAg and 
Anti-HCV Ab and regular 
consumption of drugs 
associated with fatty liver 
disease
The data of 259 subjects 
were not appropriate for 
analysis in the present study
Figure 1  Schematic diagram of study participants and exclusions criteria.
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capability was related to the 18-40 age group (AUC 
= 0.8930, 95%CI: 0.8766-0.9093), while the lowest 
accuracy was related to the 40-60 age group (AUC = 
0.8293, 95%CI: 0.8095-0.8492). The AUC for the ≥ 
60 age group was 0.8403 (95%CI: 0.8124- 0.8683). 
Although the predictive performance of FLI was 
significantly higher than BMI (AUC of BMI = 0.8258, 
95%CI: 0.8139-0.8378), TG (AUC of TG = 0.6840, 
95%CI: 0.6676-0.7004), and gamma glutamyl 
transferase (GGT) (AUC of GGT = 0.6927, 95%CI: 
0.6772-0.7081), with P < 0.0001, no significant 
difference was detected between the performance 
of FLI and WC (AUC of WC = 0.8533, 95%CI: 
0.8419-0.8646). Figure 2 shows the related ROC 
curves for FLI, WC, BMI, TG, and GGT in both men and 
women.
Gender-based optimal cutoff points of FLI were also 
obtained for FLI in the diagnosis of NAFLD. The optimal 
cutoff points of FLI were 46.9 in men (sensitivity = 
0.8242, specificity = 0.7687, Youden’s index = 0.5929) 
and 53.8 in women (sensitivity = 0.8233, specificity = 
0.7655, Youden’s index = 0.5888).
additional relevant predictor variables. Five potential 
predictor variables, including age, gender, MAP, HDL, 
and the HOMA-IR test were entered into the model in 
addition to FLI. In the multivariable model, Cox and 
Snell’s R2, as well as Nagelkerke’s R2, were calculated 
to determine how much NAFLD variance could be 
explained by the model. The Hosmer-Lemeshow test 
was used to evaluate the adequacy or suitability of the 
model. The odds ratio and related confidence intervals 
were reported along with P values. The significance 
level for all analyses was considered to be 0.05. All 
statistical analyses were conducted using version 21 
of SPSS Inc., Chicago statistical software and STATA 
software, version 12 (StataCorp, Texas, United States).
RESULTS
Table 1 shows the mean age, anthropometric cha-
racteristics, and laboratory values of the study 
participants. Significant differences were reported 
between the two sexes for all variables except TG. 
Results of ROC curve analysis
In the total population, the AUC of FLI in the diagnosis 
of NAFLD was 0.8656 (95%CI: 0.8548-0.8764), in 
which no significant difference was detected between 
men (AUC = 0.8648, 95%CI: 0.8504-0.8791) and 
women (AUC = 0.8682, 95%CI: 0.8513-0.8851). 
Analysis by age group showed that the greatest 
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Table 1  Anthropometric characteristics and laboratory values 
of participants (mean ± SD)
Characteristics Men (n  = 2860) Women (n  = 2192) P  value
Age (yr)     44.77 ± 16.77     43.78 ± 15.43    0.0216
Weight (kg)     76.70 ± 15.05     72.60 ± 14.36 < 0.0001
Height (cm) 169.94 ± 8.02 156.40 ± 7.05 < 0.0001
WC (cm)     90.76 ± 12.32     91.55 ± 13.89    0.0199
DBP (mmHg)     76.61 ± 12.69     75.82 ± 13.05    0.0191
SBP (mmHg)   117.42 ± 15.76   115.42 ± 17.60 < 0.0001
MAP (mmHg)     90.22 ± 12.90     89.01 ± 13.62
BMI (kg/m2) < 0.0001
   mean ± SD   26.46 ± 4.60   29.65 ± 5.67
   Prevalence of 
   BMI ≥ 30 (%)
21.6 (20.2-23.0) 47.3 (45.4-49.3)
TG (mg/dL) 145.55 ± 98.25   141.12 ± 95.99    0.0966
HDL (mg/dL)   43.37 ± 11.48     46.42 ± 12.08 < 0.0001
Cholesterol 178.49 ± 41.95   189.47 ± 43.20 < 0.0001
ALT (U/L)   26.46 ± 19.04     19.59 ± 14.03 < 0.0001
AST (U/L)   23.98 ± 12.65   19.98 ± 9.71 < 0.0001
GGT (U/L)   29.90 ± 28.61     25.62 ± 21.64 < 0.0001
FBS   98.62 ± 29.86   103.98 ± 41.30 < 0.0001
Insulin (mU/L)   8.87 ± 6.74   10.36 ± 6.88 < 0.0001
HOMA-IR   2.19 ± 1.90     2.72 ± 2.45 < 0.0001
FLI   45.76 ± 28.93     52.24 ± 29.87 < 0.0001
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: 
Body Mass Index; DBP: Diastolic blood pressure; GGT: Gamma glutamyl 
transferase; FBS: Fasting blood sugar; FLI: Fatty liver index; HDL: High-
density lipoprotein; HOMA-IR: Homeostasis Model Assessments-insulin 
resistance; LDL: Low-density lipoprotein; MAP: Mean arterial pressure; 
SBP: Systolic blood pressure; SD: Standard deviation; TG: Triglyceride; 
WC: Waist circumference.
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Figure 2  Receiver operating characteristic curves of fatty liver index 
and their related components. A and B were related to men and women, 
respectively. Red color dash pattern curve was related to WC, yellow color solid 
pattern curve was related to BMI, blue color dot pattern curve was related to 
GGT, purple color long dash 3-dot pattern curve was related to TG, and lime 
color dash dot pattern curve was related to FLI. BMI: Body mass index; FLI: 
Fatty liver index; GGT: Gamma glutamyl transferase; TG: Triglyceride; WC: 
Waist circumference.
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According to these cutoff points, the prevalence of 
a high FLI was 0.4809 (0.4610-0.5007) in men and 
0.5021 (0.4782-0.5260) in women. No significant 
difference was detected between the two sexes.
Results of univariate and multivariate logistic regression 
analysis
Univariate logistic regression analysis was performed 
on NAFLD by entering predictor variables, including 
age, sex, systolic blood pressure, diastolic blood 
pressure, HOMA-IR test, HDL, and FLI. The results are 
reported in Table 2.
Before conducting the multivariate model, its 
suitability and adequacy were evaluated using relevant 
specific tests. In the multi-collinearity diagnostic 
test, SBP and DBP were located in a single common 
dimension, while a variance proportion of 0.97 was 
related to SBP. As a result, we replaced SBP and DBP 
with mean arterial pressure (MAP) [MAP = DRP + 1/3 
(SBP|DBP)] multivariate model. Collinearity tests were 
rechecked before conducting multivariable logistic 
regression, with no variance proportion ≥ 0.9 related 
to predictor variables. Tolerances varied from 0.599 
to 0.951, with each predictor variable being located 
separately in a related independent dimension. In the 
multivariate model, Cox & Snell’s R2 and Nagelkerke’s 
R2 that can be explained by the model. On the other 
hand, Hosmer-Lemeshow test (χ 2 = 14.476, df = 8 and 
P = 0.07) indicated that a significant difference could 
not be established between observed and expected 
frequencies, thereby confirming the adequacy and 
suitability of our proposed model. After removing the 
effects of other predictors in the multivariable model, 
age (P < 0.001), gender (P = 0.002), MAP (P = 0.002), 
and FLI (P < 0.001) were significantly associated with 
NAFLD. FLI was highly associated with NAFLD, to the 
point that even a one-unit increase in FLI increased the 
chance of NAFLD occurrence by 5.8%. The odds ratios 
of the other predictor variables are shown in Table 2.
Table 3 shows the prevalence of NAFLD and high 
FLI, with the latter being calculated based on our study 
cutoff points; the second and third columns of the 
table are related to the prevalence of NAFLD and high 
FLI. Although an increasing trend of NAFLD prevalence 
among women was detected according to age, among 
men the prevalence was highest in the 40-59 age 
group. We observed a similar pattern for high FLI. 
DISCUSSION
The present study revealed that FLI has a high 
discriminatory power in the diagnosis of NAFLD. 
Analyses based on sex and age groups showed that 
this index has an appropriate performance in both 
sex and all age groups of 18-39, 40-59, and ≥ 60. A 
significantly strong association between NAFLD and FLI 
was also confirmed by binary regression, to the point 
that a one-unit increase in FLI led to a 5.8% increase 
in the chance of developing NAFLD. These results 
were in line with the findings of a previous study in 
which FLI showed good predictive performance in the 
diagnosis of NAFLD, with an AUC of 0.813[19]. 
This result could be somewhat anticipated due to 
the fact that FLI is composed of four quantities related 
to NAFLD, including BMI, WC, GGT, and TG[18]. A high 
BMI or WC, the main obesity indices, is considered an 
essential risk factor for NAFLD, and the prevalence of 
NAFLD substantially increases in obese individuals[21]. 
GGT can be considered an independent predictor 
for NAFLD, since this enzyme increases in NAFLD to 
protect against the adverse effects of insulin resistance 
due to its antioxidant activity[22,23]. On the other hand, 
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Table 2  Results of univariable and multivariable logistic regression analysis, including Wald tests, related P  value, and odds ratios
Variables Univariable logistic regression Multivariable logistic regression
Wald test P  value Odds ratio and CI Wald test P  value Odds ratio
Age   408.6 < 0.001 1.037 (1.033-1.040) 56.700 < 0.001 1.022 (1.016-1.028)
Gender   9.828    0.002 1.183 (1.065-1.315)   9.020    0.003 0.764 (0.641-0.911)
MAP   476.4 < 0.001 1.052 (1.047-1.057)   9.225    0.002 1.011 (1.004-1.018)
HOMA-IR   364.3 < 0.001   1.408 (1.359-1.4457)   2.402    0.121 1.036 (0.991-1.084)
HDL   273.7    0.001 0.959 (0.954-0.964)   1.381    0.240 1.005 (0.997-1.013)
FLI 1148.9 < 0.001 1.061 (1.058-1.065)   722.5 < 0.001 1.058 (1.054-1.063)
CI: Confidence interval; FLI: Fatty liver index; HDL: High-density lipoprotein; HOMA-IR: Homeostasis Model Assessments- insulin resistance; MAP: Mean 
arterial pressure.
Table 3  Prevalence of non-alcoholic fatty liver disease and a 
high fatty liver index by sex and age groups
Population Prevalence of NAFLD 
(%)
Prevalence of NAFLD 
High FLI1 (%)
Men
Total men (n = 2860) 40.1 (38.4-41.8) 48.1 (46.1-50.1)
18-39 (n = 1136) 27.3 (24.9-29.7) 37.6 (34.6-40.7)
40-59 (n =1124) 50.6 (47.8-53.3) 58.3 (55.2-61.5)
≥ 60 (600) 44.6 (40.9-48.3) 48.9 (44.6-53.2)
Women
Total women(n =2192) 44.2 (42.3-46.1) 50.2 (47.8-52.6)
18-39 (n = 902) 20.4 (17.9-22.9) 28.4 (24.9-31.8)
40-59 (n = 900) 59.4 (56.4-62.4) 63.3 (59.7-66.9)
≥ 60 (390) 64.1 (59.6-68.5) 66.4 (61.3-71.5)
1Prevalence of a high FLI based on cutoff points of 46.9 for men and 53.8 
for women. FLI: Fatty liver index; NAFLD: Non-alcoholic fatty liver 
disease.
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among the markers of dyslipidemia, TG is strongly 
associated with NAFLD[24]. However, we found no 
significant difference between the performance of 
FLI and WC. An almost equal performance between 
obesity indices and FLI could be somewhat expected, 
as although obesity is strongly associated with 
NAFLD, it is also associated with other components 
involved in the calculation of FLI, including TG and 
liver enzymes[25,26]. Insulin resistance plays a key role 
in the pathogenesis of NAFLD and there is a strong 
association between this condition and the abnormal 
components of metabolic syndrome (MetS), where 
NAFLD is considered the hepatic manifestation of 
MetS[27]. As a result, the high discriminatory capability 
of WC for NAFLD is a logical expectation due to the 
undeniable role of visceral adiposity in MetS. However, 
Koehler et al[19] obtained a slightly significantly higher 
performance for FLI than obesity indices in elderly 
inhabitants of a district of Rotterdam, the Netherlands.
This study also suggests separate optimal cutoff 
points of FLI for men and women, with values of 
46.9 and 53.8, respectively. A higher cutoff point for 
women is perhaps the result of a lower vulnerability of 
females to this condition due to the protective effect 
of estrogen, although its underlying mechanism is 
not fully understood[28,29]. Furthermore, metabolic risk 
factors alone play different roles in the development of 
NAFLD between males and females[30].
Although NAFLD has previously been discussed as 
a predominantly male condition, our study obtained 
a significantly higher prevalence of it among women 
compared to men[31]. This disagreement may be partly 
attributed to the markedly higher prevalence of obesity 
among women (47.3%) compared to men (21.6%). 
On the other hand, despite a higher estimation of 
NAFLD among women, our results appear to confirm 
that the female sex has a protective mechanism 
against this disease. In univariable analysis, women 
seemed to show greater odds than men for developing 
NAFLD, but by removing the effects of other predictors 
in the multivariable model, an inverse result was 
obtained which indicated that a higher chance of 
NAFLD was related to the male sex. On the other 
hand, men had a higher prevalence of NAFLD in the 
under-40 age group than women, while prevalence 
was higher in women than men in the over-60 age 
group, perhaps as a result of an attenuated protective 
effect of estrogen against NAFLD in menopausal 
women. Moreover, the prevalence of fatty liver among 
men was reduced in the over-60 age group compared 
with the 40-60-year-old group, which could be due 
to the declining effects of male sexual hormones with 
age[32].
Our study had a population-based design and a 
large sample size in which a reliable non-invasive 
approach was applied to diagnose NAFLD. Although 
liver biopsy is the gold standard for diagnosis of fatty 
liver disease, this approach is not only invasive, but 
also has a relatively high false negative rate in the 
diagnosis of this condition[10-12,33]. As a result, it may 
be better that a multifaceted non-invasive approach is 
implemented in order to diagnose NAFLD in population-
based studies until a more reliable evaluation can be 
obtained from the performance of FLI. 
In conclusion, FLI has a promising predictive power 
in the diagnosis of NAFLD. However, according to our 
findings, FLI was not more effective than WC in the 
discrimination of NAFLD. While the performance of 
FLI was not different between the two sexes, a higher 
cutoff point of FLI was obtained for women than men. 
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